A Dosing Study of Hyperbaric Oxygen Therapy (HBOT) on Epigenetic Aging

NCT05297019 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2023-04-12

No results posted yet for this study

Summary

This study aims to assess the impact of hyperbaric oxygen therapy on a number of outcomes, including epigenetic aging, inflammation, and cellular health.

Conditions

  • Aging

Interventions

PROCEDURE

Hyperbaric Oxygen Therapy

hyperbaric oxygen therapy

Sponsors & Collaborators

  • TruDiagnostic

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
40 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-03-01
Primary Completion
2023-04-30
Completion
2023-07-01

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05297019 on ClinicalTrials.gov